APA (7th ed.) Citation

Lang, W., He, Y., Hou, C., Li, H., Jiang, Q., & Mei, L. Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in the Chinese healthcare system. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Lang, Wenwang, Yulong He, Changchun Hou, Hua Li, Qinling Jiang, and Liuyong Mei. Cost-effectiveness Analysis of Pembrolizumab Plus Chemotherapy Versus Chemotherapy in Untreated Advanced Pleural Mesothelioma in the Chinese Healthcare System. Frontiers Media S.A.

MLA (9th ed.) Citation

Lang, Wenwang, et al. Cost-effectiveness Analysis of Pembrolizumab Plus Chemotherapy Versus Chemotherapy in Untreated Advanced Pleural Mesothelioma in the Chinese Healthcare System. Frontiers Media S.A.